Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide

Diabetes and Metabolism

Volumn 35, Issue 4, 2009, Pages 293-298

  Del Guerra, S ^a   D'Aleo, V ^a   Lupi, R ^a   Masini, M ^a   Bugliani, M ^a   Boggi, U ^a   Filipponi, F ^a   Marchetti, P ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Glibenclamide; Gliclazide; Ki67; Pancreatic islets; PDX 1

Indexed keywords

COLLAGENASE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; KI 67 ANTIGEN; MARKER; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BODY MASS; CELL CULTURE; CELL ISOLATION; DIGESTION; DRUG EFFECT; ELECTRON MICROSCOPY; FEMALE; GENDER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN RELEASE; MALE; ORGAN DONOR; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PURIFICATION;

AGED; ANALYSIS OF VARIANCE; CELLS, CULTURED; FEMALE; GLICLAZIDE; GLUCOSE; GLYBURIDE; HOMEODOMAIN PROTEINS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PANCREAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DONORS; TRANS-ACTIVATORS;

EID: 70349254097     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.01.004     Document Type: Article

References (41)

1. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
2. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51 (2008) 8-11
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
5. Palmer K.J., and Brogden R.N. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46 (1993) 92-125
6. Patel A., and the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
7. Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 52 Suppl 1 (2003) 29-34
8. Proks P., Reimann F., Green N., Gribble F., and Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 51 Suppl 3 (2002) S368-S376
9. Gribble F.M., and Ashcroft F.M. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 42 (1999) 845-848
10. Jennings P.E., and Belch J.J. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism 49 Suppl 1 (2000) 23-26
11. Ceriello A. Effects of gliclazide beyond metabolic control. Metabolism 55 Suppl 1 (2006) S10-S15
12. Räkel A., Renier G., Roussin A., Buithieu J., Mamputu J.C., and Serri O. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab 9 (2007) 127-129
13. Monami M., Balzi D., Lamanna C., Barchielli A., Masotti G., Buiatti E., et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 23 (2007) 479-484
14. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., Katsuta H., et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 303 (2003) 112-119
15. Del Guerra S., Grupillo M., Masini M., Lupi R., Bugliani M., Torri S., et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 23 (2007) 234-238
16. Marchetti P., Del Guerra S., Marselli L., Lupi R., Masini M., Pollera M., et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89 (2004) 5535-5541
17. Del Guerra S., Lupi R., Marselli L., Masini M., Bugliani M., Sbrana S., et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54 (2005) 727-735
18. Mandal U., Ray K.K., Gowda V., Ghosh A., and Pal T.K. In-vitro and in-vivo correlation for two gliclazide extended-release tablets. J Pharm Pharmacol 59 (2007) 971-976
19. Marchetti P., and Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet 16 (1989) 100-128
20. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-804.
21. Marchetti P., Bugliani M., Lupi R., Marselli L., Masini M., Boggi U., et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50 (2007) 2486-2494
22. Lupi R., Del Guerra S., Tellini C., Giannarelli R., Coppelli A., Lorenzetti M., et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 364 (1999) 205-209
23. Davalli A.M., Pontiroli A.E., Socci C., Bertuzzi F., Fattor B., Braghi S., et al. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than beta-cell exhaustion. J Clin Endocrinol Metab 74 (1992) 790-794
24. Hou ZQ, Li HL, Gao L, et al. Involvement of chronic stresses in rat islets and INS-1 cell glucotoxicity induced by intermittent high glucose. Mol Cell Endocrinol 2008.
25. Piconi L, Quagliaro L, Assaloni R, et al. Constant and intermittent high glucose enhance endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 2006;22:198-203.
26. Ling Z., Kiekens R., Mahler T., Schuit F.C., Pipeleers-Marichal M., Sener A., et al. Effects of chronically elevated glucose levels on the functional properties of rat pancreatic beta-cells. Diabetes 45 (1996) 1774-1782
27. Dubois M., Vacher P., Roger B., Huyghe D., Vandewalle B., Kerr-Conte J., et al. Glucotoxicity inhibits late steps of insulin exocytosis. Endocrinology 148 (2007) 1605-1614
28. Poitout V., and Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29 (2008) 351-366
29. Federici M., Hribal M., Perego L., Ranalli M., Caradonna Z., Perego C., et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50 (2001) 1290-1301
30. Kaneto H., Miyatsuka T., Shiraiwa T., Yamamoto K., Kato K., Fujitani Y., et al. Crucial role of PDX-1 in pancreas development, beta-cell differentiation, and induction of surrogate beta-cells. Curr Med Chem 14 (2007) 1745-1752
31. Brown D.C., and Gatter K.C. Ki67 protein: the immaculate deception?. Histopathology 40 (2002) 2-11
32. Robertson R.P., Zhang H.J., Pyzdrowski K.L., and Walseth T.F. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest 90 (1992) 320-325
33. Yamato E., Ikegami H., Tahara Y., Fukuda M., Cha T., Kawaguchi Y., et al. Glyburide enhances insulin gene expression and glucose-induced insulin release in isolated rat islets. Biochem Biophys Res Commun 199 (1994) 327-333
34. Tiedge M., and Lenzen S. Effects of glucose refeeding and glibenclamide treatment on glucokinase and GLUT2 gene expression in pancreatic B-cells and liver from rats. Biochem J 308 (1995) 139-144
35. Ball A.J., McCluskey J.T., Flatt P.R., and McClenaghan N.H. Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components. Pharmacol Res 50 (2004) 41-46
36. Hahn P.J., Lai Z.W., Nevaldine B., Schiff N., Fiore N.C., and Silverstone A.E. Bcl2-independent chromatin cleavage is a very early event during induction of apoptosis in mouse thymocytes after treatment with either dexamethasone or ionizing radiation. Radiat Res 160 (2003) 559-567
37. Butler P.C., Meier J.J., Butler A.E., and Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 3 (2007) 758-768
38. Bonner-Weir S., and Sharma A. Are there pancreatic progenitor cells from which new islets form after birth?. Nat Clin Pract Endocrinol Metab 2 (2006) 240-241
39. Nakano N., Miyazawa N., Sakurai T., Kizaki T., Kimoto K., Takahashi K., et al. Gliclazide Inhibits Proliferation but Stimulates Differentiation of White and Brown Adipocytes. J Biochem (Tokyo) 142 (2007) 639-645
40. Guiot Y., Henquin J.C., and Rahier J. Effects of glibenclamide on pancreatic beta-cell proliferation in vivo. Eur J Pharmacol 261 (1994) 157-161
41. Satoh J., Takahashi K., Takizawa Y., Ishihara H., Hirai M., Katagiri H., et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 70 (2005) 291-297